Clinical trials: PD-1 Antibody
Small-cell Lung Cancer
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
This study is conducted in patients with advanced metastatic small cell lung cancer (SCLC). This study includes a single arm: the patients will receive HLX07 combination therapy with HLX10 and chemotherapy (carboplatin+etoposide)…
- Trial name
- NCT05354700
- Testing
- HLX07, HLX10, carboplatin and etoposide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
- Trial name
- NCT03940001
- Testing
- Sintilimab, carboplatin/paclitaxel, Radiation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
NK/T Cell Lymphoma Nos
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
The purpose of this randomized, multi-center,phase Ⅲ clinical trail is to compare the safety and efficacy of sequencial chemoradiotherapy with or without toripalimab (PD-1 antibody) for newly diagnosed early-stage extranodal…
- Trial name
- NCT04365036
- Testing
- Toripalimab, Pegaspargase, Gemcitabine
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Sun Yat-sen University
Advanced or Metastatic Solid Tumors
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of HLX60 combined with HLX10 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy…
- Trial name
- NCT05483530
- Testing
- HLX60 combined with HLX10
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT03779100
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shi Ming
Biphasic Mesothelioma, Epithelioid Mesothelioma
Pembrolizumab in Treating Patients With Malignant Mesothelioma
This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum).
- Conditions
- Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma
- Trial name
- NCT02399371
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Chicago
pMMR/MSS Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）
Safety and efficacy of Short-Course Radiotherapy Followed by Sequential Chemotherapy with or without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.
- Trial name
- NCT07005570
- Testing
- Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab, Short-course radiotherapy followed by sequential chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Dechang Diao
NSCLC, Locally Advanced
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced…
- Trial name
- TRIPL (NCT06865339)
- Testing
- Cemiplimab, Fianlimab, Radiotherapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Montefiore Medical Center
Non-small Cell Lung Cancer
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
This study targets patients with in first-line treatment of advanced NSCLC， enrolling 60-84 participants. Patients will receive Arm 1: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Pemetrexed (500 mg/m2 IV, D1) + a platinum (carboplatin…
- Trial name
- NCT06969027
- Testing
- JS207, Pemetrexed injection, Platinum
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Solid Tumor, Glioblastoma
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma…
- Conditions
- Solid Tumor, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain
- Trial name
- NCT05095441
- Testing
- C5252
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- ImmVira Pharma Co. Ltd
HCC, Transarterial Chemoembolization
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1…
- Conditions
- HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Regorafenib
- Trial name
- NCT05025592
- Testing
- Regorafenib, cTACE/DEB-TACE-HAIC
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Human Immunodeficiency Virus (HIV), HIV Infection
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1
This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in…
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
- Trial name
- NCT04223804
- Testing
- ABBV-181
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Gastric Cancer
Combination of TATE and PD-1 Inhibitor in Liver Cancer
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab).
- Trial name
- TATE-PD1 (NCT03259867)
- Testing
- Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Teclison Ltd.
Gastric Adenocarcinoma
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
This is a single-center, single-arm, phase 2 clinical study testing a new neoadjuvant (pre-surgery) treatment for patients with locally advanced gastric cancer or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT07867392
- Testing
- Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1）
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Melanoma
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
This study will assess whether post-surgery therapy with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo for high-risk participants with melanoma (Stage IIIA [> 1 mm metastasis], IIIB and IIIC).
- Trial name
- NCT02362594
- Testing
- pembrolizumab
- Volunteers
- 1,019 people
- Sponsor
- Merck Sharp & Dohme LLC
Adrenocortical Carcinoma
Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma
Adrenal cortical cancer is an extremely rare and highly aggressive malignancy with an incidence of 0.7-2 per million people · year and a 5-year overall survival rate of 15-44%, among which the 5-year survival rate of stage IV…
- Trial name
- NCT06587802
- Testing
- Triprolizumab, rodiotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.